The pharma industry briefing

The latest news, approvals and clinical trials you need to know about this month

Data:
News
in Numbers

 $226m 

Sanofi has been awarded a $226m contract to boost vaccine supplies in US

 2020 

Gilead’s Kite unit is set to launch its latest CAR-T therapy by mid-2020

58% 

The overall response rate achieved by Kymriah in adults with relapsed/refractory diffuse large B cell lymphoma

200,000

The number of doses J&J plans to deploy of its investigational Ebola vaccine in Rwanda 

 ¥ 4bn

Fujifilm’s ¥ 4bn ($37.5m) liposome plant has been completed and is scheduled to begin operation in February 2020

Data:
News
in Numbers

$226m 

Sanofi has been awarded a $226m contract to boost vaccine supplies in US

2020 

Gilead’s Kite unit is set to launch its latest CAR-T therapy by mid-2020

 58%

The overall response rate achieved by Kymriah in adults with relapsed/refractory diffuse large B cell lymphoma

200,000 

The number of doses J&J plans to deploy of its investigational Ebola vaccine in Rwanda 

¥ 4bn

Fujifilm’s ¥ 4bn ($37.5m) liposome plant has been completed and is scheduled to begin operation in February 2020

 Once-a-month contraceptive pill developed by scientists

Gelatine capsule could prevent unplanned pregnancies caused by errors in daily pill use

Source: the Guardian

 Research shows the pharma industry believes AI will likely optimise R&D

A survey has shown that the pharmaceutical industry believes R&D will see a lot of benefit from digital transformation and that AI will be at the forefront.

Source: Drug Target Review 

 UK’s PinPoint gets funding to develop early stage cancer blood test

UK-based AI and machine learning firm PinPoint has raised more than £1m to develop a test designed to rule out cancer in the early stages and save millions for the NHS in unnecessary testing.

Source: Pharmaphorum

 Leukaemia, lymphoma squarely in sights of new class of drugs

UT Health San Antonio researchers, working with collaborators at the University of Florida, have discovered a safe and potent next generation of drugs to fight multiple types of leukemia and lymphoma in adults and children. 

Source: World Pharma News

Approvals

 etectRx

The US FDA has approved an ingestible event marker from the privately-held digital health company etectRx.

Source: etectRx

Avsola (infliximab-axxq)

THE US FDA has approved Avsola for the treatment of moderate-to-severe rheumatoid arthritis, moderate-to-severe Crohn's Disease in the adult and paediatric population, moderate-to-severe ulcerative colitis in the adult and paediatric population, chronic severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis.

Source: Amgen

Olaparib

Olaparib tablets will now be available for patients in Scotland with newly-diagnosed BRCA-mutated advanced ovarian cancer who have responded to chemotherapy.

Source: BBC

KALYDECO® (ivacaftor)

The European Commission has approved the label extension for KALYDECO® (ivacaftor) to include the treatment of infants with cystic fibrosis between six and 12 months old.

Source: Vertex

Go to top